Catalent has launched its new OneXpress service for the integrated development, scale up and manufacturing of new oral solid dosage forms.
 
The OneXpress solution aims to accelerate a program’s transition from early-phase development to commercial-ready manufacturing leveraging Catalent’s phase-appropriate scale, technologies, oral dose form network and expertise to reduce risk, complexity and cost between phases. According to the company, by eliminating the need to transition projects between multiple service providers, duplication of tasks can be avoided, API consumption can be reduced, and drug products can reach patients faster.
 
With an integrated global network and streamlined program management, the OneXpress solution combines the expertise at Catalent’s early-phase drug development centers in Nottingham, U.K., Somerset, NJ, and San Diego in the U.S. with Catalent’s oral solid commercial manufacturing facilities.
 
“The oral drug development path is lengthy and complex, so to maximize speed and flexibility and reduce costs, innovators need to select development partners with the expertise and capabilities that are best suited for each stage in their development cycle,” commented Jeremie Trochu, Vice President, Oral and Specialty Delivery at Catalent. “Our teams have collaborated across sites to harmonize equipment, materials and protocols, to ensure accelerated and seamless scale up from first-in-human trials to commercial launch. We successfully transferred over a dozen OneXpress projects in the last year alone.”